Exact Sciences to buy cancer-screening firm Thrive Earlier Detection in $2.15 bln deal

Credit: REUTERS/Rick Wilking

Oct 27 (Reuters) - Exact Sciences Corp EXAS.O said on Tuesday it would buy cancer-screening firm Thrive Earlier Detection Corp in a cash-and-stock deal that could be valued up to $2.15 billion.

Exact Sciences said it expects to expand its cancer detection portfolio with Thrive's lead early-stage screening test, CancerSEEK, which successfully detected 10 different types of cancer in a 10,000-patient study in April.

Thrive will get $1.7 billion, comprising 65% of Exact Sciences' common stock and 35% in cash, under terms of the deal. An additional $450 million is payable upon completion of certain milestones.

The companies expect to close the deal in the first quarter of 2021.

(Reporting by Trisha Roy in Bengaluru; Editing by Ramakrishnan M.)

((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.